Journal of Pediatric Neurology 2003; 01(01): 029-034
DOI: 10.1055/s-0035-1557166
Original Article
Georg Thieme Verlag KG Stuttgart – New York

Botulinum toxin A in children with cerebral palsy: evaluation of therapy using the Pediatric Evaluation of Disability Inventory (PEDI)

Volker Mall
1   Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg, Germany
,
Janbernd Kirschner
1   Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg, Germany
,
Michaela Linder
1   Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg, Germany
,
Gudrun Schindler
1   Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg, Germany
,
Steffen Berweck
2   Children's Hospital, University of Munich, Germany
,
Sabine Stein
1   Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg, Germany
,
Ulla Michaelis
1   Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg, Germany
,
Peter Bernius
3   Department of Orthopedics, Munich-Harlaching Hospital, Germany
,
Rudolf Korinthenberg
1   Department of Neuropediatrics and Muscular Disorders, Children's Hospital, University of Freiburg, Germany
,
Florian Heinen
2   Children's Hospital, University of Munich, Germany
› Institutsangaben

Verantwortlicher Herausgeber dieser Rubrik:
Weitere Informationen

Publikationsverlauf

14. März 2003

19. Juni 2003

Publikationsdatum:
29. Juli 2015 (online)

Abstract

Several controlled studies have shown that in children with cerebral palsy, botulinum toxin A (BTX/A) can decrease muscular hyperactivity associated with spasticity and improve function. Studies have hitherto focused on the dimensions of impairment and functional limitations. In this pilot study with BTX/A in children with cerebral palsy, we used the Pediatric Evaluation of Disability Inventory (PEDI) to evaluate the effect of treatment. PEDI is a reliable and valid instrument that focuses on assessing disability in daily life. Patients with cerebral palsy (n = 17, median age 5.5 years, age range 2.5 to 16.5 years) were treated with BTX/A for pes equinus (n = 8) or adductor spasm (n = 9). PEDI assessment was carried out before and 1 month after the first treatment with BTX/A. Scaled scores were calculated according to the user’s manual for the Mobility domain with scores near „0” reflecting low capability and scores near „100” reflecting high capability. We found a significant improvement in the mobility domain-caregiver dimension from 52.3% ± 26.6% to 56.6% ± 26.7% (mean, standard deviation P < 0.05), as well as in the self care domain-functional skills from 63.6% ± 18.7% to 65.2% ± 19.6% (mean, standard deviation P < 0.05). Our data indicate that in young patients with cerebral palsy, BTX/A therapy of the lower extremity can reduce the disability. For these patients PEDI is a valuable assessment instrument that reflects the effect of treatment with BTX/A on the disability. (J Pediatr Neurol 2003; 1(1): 29–34).